B

디티앤씨알오

383930KOSDAQ자연과학 및 공학 연구개발업

66.8 / 100

Reference Date: 2026-04-13

Financial Score20.5 / 40
News Sentiment21.3 / 25
Momentum15.0 / 20
Disclosure10.0 / 15
AI Analysis: PBR is significantly undervalued vs. peers but the high debt ratio poses financial risk. Surged 19.1% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

DT&CR is a Full-Service CRO providing non-clinical and clinical trial services across pharmaceuticals, medical devices, and health functional foods, offering integrated solutions from early-stage drug development to FDA approval. In 2025, revenue increased by 32.7% year-over-year to 47.7 billion won, driven by specialized services such as the expanded PK/PD center, which scientifically analyzes drug candidate characteristics.

Number of Employees

314people

Average Salary

47.4M KRW

Score Calculation Basis

Detailed Financial Score

PER
Industry Average 120.074.0Point
PBR
1.88Industry Average 3.827.0Point

Half of industry avg (excellent)

ROE
-10.33Industry Average -32.113.5Point

Well below industry avg

Debt Ratio
54.18Industry Average 7.520.0Point

7.2x industry avg (risky)

Trend 2023~20256.0 / 10 points
Revenue Growth Rate
3.0 / 3

Avg ▲34.0% (2-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲28.0% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -19.9% (improving, 3yr)

Detailed News Sentiment

5 totalPositive 5Neutral 0Negative 0Average Sentiment Score 85

Detailed Momentum

52-week position3.0Point

52w lower range (26%)

Current 3,680Won52-week high 7,49052-week low 2,320
1-month return6.0Point

1m +19.09% (strong rise)

Volume trend6.0Point

Volume surge

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0
  • Neutral정기주주총회결과2026-03-30
  • Neutral감사보고서제출2026-03-20
  • Neutral사업보고서 (2025.12)2026-03-20